Cardiac Amyloid Deposits and Heart Dysfunction in Alzheimer's Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Dementia, Alzheimer Type, Mild Cognitive Impairment, Cardiac Amyloidosis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Germany
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Investigation of Cardiac Amyloid Deposits as a Cause of Cardiac Dysfunction in Alzheimer's Disease (Untersuchung Von Kardialen Amyloidablagerungen Als Ursache Einer Funktionseinschränkung Des Herzens Bei Alzheimer Demenz)
Overview
This study seeks to explore the possible common pathogenesis of both cardiac amyloidosis and Alzheimer's disease, which can both be associated with amyloid deposits. Using Positron Emission Tomography (PET) scans with amyloid tracers - a conventional tool for non-invasively imaging amyloid deposits in Alzheimer's disease - the research will extend this imaging methodology to the heart. The study will conduct additional PET/MRI scans of the heart in patients undergoing amyloid tracer PET scans for Alzheimer's evaluations. Each participant will also undergo an echocardiogram and a clinical examination of dementia. This could potentially enhance diagnostic practices in both cardiac amyloidosis and Alzheimer's disease.
Primary outcome measures
- Frequency of occurrence of cardiac amyloid deposits in patients with a diagnosis of Alzheimer's disease (overall) [Time frame: through study completion, an average of 1 year]
- Frequency of occurrence of cardiac amyloid deposits in relation to different disease manifestations (subdivided, for example, by clinical assessment of disease stage) [Time frame: through study completion, an average of 1 year]
Eligibility criteria
Inclusion criteria
- Patients undergoing cerebral amyloid PET examination for clinical indication to clarify Alzheimer's disease
- No contraindications to undergo an MRI examination
- No contraindications to undergo an Amyloid PET scan
Exclusion criteria
- Patients with vascular dementia and confirmed other causes of dementia (e.g. stroke, vitamin deficiency, thyroid insufficiency, toxic causes such as alcohol)
- Patients with pronounced cardiac preconditions
- Pregnant and breastfeeding women
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Germany · 1 center
- University Hospital Essen — Essen
Identifiers
NCT: NCT07154394 · 20-9291-BO